🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Financials Sector SEC Filings — February 27, 2026

Across 241 SEC filings from S&P 500 Financials on Feb 27, 2026, overarching themes include mixed earnings with revenue growth in insurers (AXIS GPW +7% YoY to $9.6B) and turnarounds (HEI FY net income $123M from -$1.4B loss, core +20%), but declines in REITs/hotels (Apple Hospitality RevPAR -1.6% YoY FY2025, EBITDA margin -190bps to 34.3%) and occupancy pressures (Saul Centers commercial 94.6% down from 95.2%). Capital allocation robust with AXIS >$1B returns, Apple $58.3M buybacks (4.6M shares), Healthcare Realty $50M repurchases; financings prevalent (Wyndham $650M notes, Tandem $200M convertibles). Delisting risks cluster in small caps (Datavault, reAlpha, Envoy), while M&A catalysts emerge (Carnival DLC unification April 17 vote, FirstSun/First Foundation approvals). Forward guidance positive in pockets (Gogo 2026 rev $905-945M +FCF $90-110M, Healthcare Realty SS NOI 3.5-4.5%). Sentiment mixed (positive 20%, bearish 10%), with portfolio-level trends showing avg revenue +5-10% YoY in winners but -1-5% in laggards, implying selective rotation to insurers/strong balance sheets amid financing/debt trends.

107 high priority 134 medium 241 total filings
· daily

US Material Events SEC 8-K Filings — February 27, 2026

Across 97 8-K filings from February 27, 2026, dominant themes include aggressive capital raising via debt issuances ($200M-$2.5B notes across Tandem, Wyndham, Royal Caribbean, etc.), equity offerings/ATM programs (e.g., $15M Birchtech, $1.75B American Healthcare REIT), and SPAC IPOs ($125M-$261M), signaling robust liquidity pursuits amid neutral-to-positive sentiment in 70% of cases. M&A highlights feature Paramount Skydance's $81B acquisition of Warner Bros. Discovery (7.5x 2026 EBITDA) and Netflix's $2.8B termination fee from the failed WBD deal, reshaping media landscapes. Governance churn is prevalent (25+ officer/director changes, mostly retirements without disagreements), while distressed financings (e.g., 28.6% discount notes for IMAC) and delistings (reAlpha, Avidity) flag microcap risks. No broad period-over-period trends emerge due to event-driven nature, but forward-looking catalysts like Q3 2026 WBD close, annual meetings (e.g., May 2026), and note maturities (18-36 months) dominate. Portfolio implications favor large-cap refinancings reducing costs (e.g., Wyndham, WESCO) over small-cap dilution risks, with media/tech outliers driving alpha.

97 high priority 97 total filings
· daily

S&P 500 Technology Sector SEC Filings — February 27, 2026

Across these 10 S&P 500 Technology stream filings dated Feb 27, 2026, disclosures are predominantly neutral with limited quantitative enriched data, featuring sparse period-over-period trends dominated by Apple Hospitality REIT's (APLE) FY2025 revenue decline of 1.1% YoY and EBITDA margin contraction of 190 bps to 34.3%, alongside Q4 RevPAR drop of 2.6% YoY. Governance events prevail, including a DNOW board member opting not to reelect (no disagreement), Jewett-Cameron AGM with significant shareholder opposition to executive comp (611,957 against votes), and compensatory arrangements at Smurfit Westrock and Iridium Communications. Forward-looking elements include APLE's preliminary Jan 2026 RevPAR down ~1.5% YoY, Intuitive Machines' SEC registration deadline of April 1, 2026, and Iridium's Q1 2026 10-Q for comp plan exhibits. Capital allocation highlights APLE's 4.6M share repurchase for $58.3M and strong balance sheet (35% net debt to cap). Sentiment is neutral in 8/10 filings, mixed in APLE and Jewett due to softening demand offset by buybacks and passed resolutions despite opposition. Portfolio-level implication: low materiality overall (avg 5.2/10), signaling stable but unexciting tech-adjacent operations with watch for dilution risks from registrations and governance pushback.

4 high priority 6 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — February 27, 2026

The 15 NASDAQ-100 8-K filings dated February 27, 2026, are dominated by earnings-related disclosures (TXNM Energy, NIQ Global Intelligence, Alpha Metallurgical x2) under Items 2.02/7.01 without specific metrics, suggesting quiet period filings ahead of full reports with high materiality (avg 7/10). Netflix's termination of the WBD merger yielded a $2.8B fee, a major cash positive offsetting lost streaming assets amid media M&A volatility. Apple Hospitality REIT disclosed FY2025 results with revenue down 1.1% YoY to $1.4B, RevPAR -1.6% YoY to $117.95, Q4 EBITDA -8.4%, and Jan 2026 RevPAR -1.5%, but countered with $58.3M buybacks and 35% net debt-to-cap. Governance events include Comcast's audit committee addition, Smurfit Westrock officer comp changes, Iridium incentive plans, and Jewett-Cameron's AGM with strong opposition to exec comp (612k against votes). Limited period-over-period data highlights hospitality weakness as the sole quantitative trend, contrasting neutral-to-mixed sentiment portfolio-wide. Amazon's undisclosed material agreement and Intuitive Machines' registration rights add opacity-driven catalysts. Overall, neutral backdrop with actionable cash (Netflix), buybacks (APLE), and exhibit-dependent earnings insights.

6 high priority 9 medium 15 total filings
· daily

Dow Jones 30 Stocks SEC Filings — February 27, 2026

Across 84 SEC filings from February 27, 2026, primarily 8-Ks, a dominant theme is the kickoff of Q4/FY2025 earnings season with 20+ Item 2.02 disclosures (e.g., AXIS Capital, BrightSpring, Delek US), revealing mixed period-over-period trends: revenue growth in insurance (AXIS +7% YoY GPW to $9.6B) contrasted with declines in REITs/hospitality (Apple Hospitality -1.1% YoY revenue, -1.6% RevPAR) and media (Warner Bros Discovery -5% YoY revenue to $37.3B). Capital allocation shines with $1B+ returns at AXIS, Apple Hospitality's 4.6M share buyback ($58.3M), and debt reductions (Fold Holdings extinguished $66.3M notes, Presurance $14M rights proceeds). Forward-looking catalysts cluster around M&A (Carnival DLC unification vote April 17, FirstSun merger approved, Warner Bros Discovery $81B acquisition by PSKY closing Q3 2026) and clinical trials (NeOnc March 4 call). Bearish outliers include delistings (Datavault AI, Envoy Medical, Avidity Biosciences implied), biotech setbacks (Aardvark trial pause, Disc Medicine 20% workforce cut), and distressed financing (IMAC 28.6% discount note). Portfolio-level patterns show resilient financials/insurance vs. pressured consumer-facing (hotels down RevPAR -1.5-2.6% YoY) amid no broad insider selling but neutral board churn; actionable now: favor capital returners, avoid delisting risks.

36 high priority 48 medium 84 total filings
· daily

US SEC Filings Daily Market Digest — February 27, 2026

Across 298 SEC filings dated February 27, 2026, a dominant theme is earnings season with 50+ Item 2.02 disclosures (e.g., Amneal Pharma, Cigna, BrightSpring), mostly neutral due to undisclosed metrics, signaling steady but unremarkable Q4/FY2025 results amid quiet markets. Portfolio-level trends show mixed performance: revenues grew YoY in detailed reporters like US Antimony (record highs), Precipio (+30%), American Integrity (+23% premiums), but declined in others like Where Food Comes From (-3.3%), Gogo (ATG aircraft -9%); margins compressed in REITs/hospitality (Apple Hospitality EBITDA -190 bps) while improving in insurance (American Integrity combined ratio -17 ppts). Critical developments include 5 delistings/notices (Datavault AI, reAlpha Tech, Envoy Medical bearish; Sphere 3D regains compliance bullish), $2.8B Netflix termination fee from failed WBD deal, and $200M+ capital raises/debt refinancings (Tandem Diabetes, Ameren $891M bonds, Wyndham $650M notes). M&A activity surged with 20+ Item 1.01 (e.g., Amazon, AIR Industries neutral), insider changes neutral, but positive capital allocation via dividends/buybacks in 15+ (Healthcare Realty $50M repurchases, REIT distributions). Sector patterns favor energy/mining (US Antimony contracts), REITs (guidance intact), but flag biotech delistings and accounting restatements (Elauwit non-reliance). Implications: Favor defensive dividend payers/turnarounds; avoid small-cap delisting risks; monitor Q1 guidance for margin trends.

115 high priority 183 medium 298 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — February 27, 2026

Across 50 filings in the S&P 500 Consumer Discretionary intelligence stream (with broader SEC captures), neutral sentiment dominates (70%+ filings) amid frequent board/officer changes and undisclosed Reg FD items, but mixed earnings reveal revenue declines averaging -4% YoY where reported (e.g., Where Food -3.3% FY2025, Topgolf Callaway -1.9% H1 2025) offset by margin gains (Topgolf +150 bps Q1 gross margin) and operating income growth (Topgolf +7.2% H1). Key CD highlights include Amazon's undisclosed material agreement (materiality 8/10), Netflix's $2.8B termination fee from failed WBD acquisition (materiality 10/10), and Avis Budget's resolving shareholder suits. Portfolio trends show positive capital allocation via buybacks ($858M FTI, 183k shares Where Food), debt cleanups (Fold $66.3M extinguished), and issuances ($600M HA, $200M PennantPark), signaling financial flexibility despite no insider trading patterns disclosed. M&A resolutions (First Foundation/FirstSun approvals, Netflix termination) build a catalyst calendar into Q2 2026, implying sector resilience in entertainment/retail but caution on growth amid losses (Sable $410M FY2025). Actionable: Favor debt deleveraging plays; monitor merger closes and dividend records for near-term pops.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — February 27, 2026

Across 23 filings from the USA S&P 500 Healthcare stream (with some adjacent financials/REITs), dominant themes include neutral board departures (5/23 filings, e.g., Lifeward, Pulse Biosciences, Western New England), Nasdaq compliance threats in biotechs (4/23, Jupiter Neurosciences, Ensysce Biosciences, CIMG, Avidity Biosciences), and limited financial disclosures showing one standout positive (Precipio's 30% YoY revenue growth to $24M, EBITDA inflection to +$1.23M). Period-over-period trends are sparse but highlight Precipio's outperformance with 23% Q4 revenue growth and positive adjusted EBITDA ($0.95M vs $0.40M prior), contrasting Disc Medicine's negative restructuring (20% workforce cut, $2M Q1 charges post-FDA setback). Capital allocation features steady dividends (Triumph Financial $0.44525/depositary share payable Mar 30) and ATM equity raises (Bridgewater $50M, FrontView $75M), signaling liquidity needs amid compliance risks. Portfolio-level patterns reveal biotech vulnerability to delisting (materiality 9/10 average), mixed AGM support (Jewett-Cameron), and high-risk M&A/change-of-control (Avidity). Most critical: Biotech delisting cascades could pressure sector liquidity; actionable now via short-term trades on compliance deadlines (Aug 2026) and Precipio's April catalyst.

11 high priority 12 medium 23 total filings
· daily

Global High-Priority Regulatory Events — February 27, 2026

Across 140 filings centered on February 27, 2026, dominant themes include robust debt refinancing and issuance activity (e.g., Wyndham $650M notes, WESCO $1.5B at lower 5.25-5.50% rates vs prior 7.25%), SPAC IPOs and business combinations (e.g., Clearthink $125M, Mozayyx $261M, IQM/RAAQ quantum computing deal), and frequent executive changes/departures (neutral in 20+ cases like Tandem, Iridium, Western New England). Bearish pressures from Nasdaq delisting/deficiency notices (9 cases: Datavault, reAlpha, Envoy, Jupiter, Ensysce, Tenon, CIMG) and insolvencies (10+ medium-risk, mostly Indian firms like Heranba, Reliance). Warner Bros. Discovery's 10-K shows revenue -5% YoY to $37.3B but operating income turnaround from -$10B loss to $738M profit, with Streaming EBITDA +102% to $1.37B; no broad PoP trends but aggregate capital raises exceed $5B+. Media M&A peaks with PSKY $81B WBD takeover (7.5x 2026 EBITDA) and Netflix $2.8B termination fee. Portfolio implication: Favor liquidity-strong firms amid small-cap listing risks; watch Q3 2026 deal closes.

140 high priority 140 total filings
· daily

US Earnings Financial Results SEC Filings — February 27, 2026

Warner Bros. Discovery's 2025 10-K filing reveals a mixed performance with total revenues declining 5% YoY to $37.3B amid sharp drops in Global Linear Networks (-12%), advertising (-10%), and content (-6%), underscoring the structural decline in legacy TV and ad markets. However, the company staged a dramatic profitability turnaround, swinging to operating income of $738M from a $10.0B loss and net income available to WBD of $727M from an $11.3B loss, driven by Streaming revenues +5% YoY, Studios +9% YoY, and Streaming Adjusted EBITDA surging to $1,370M from $677M. Cost efficiencies were pivotal, with impairments/losses on dispositions plummeting 98% to $172M and depreciation/amortization down 19% to $5,684M, though total Adjusted EBITDA dipped 3% to $8.7B. This reflects a broader media sector pivot to streaming amid cord-cutting pressures, positioning WBD as a turnaround story but with ongoing legacy revenue risks. Mixed sentiment (10/10 materiality) signals investor caution on growth sustainability versus profitability gains. Portfolio-level insight from this sole filing highlights media companies' need for aggressive cost cuts to offset revenue headwinds, creating selective buy opportunities in streaming-focused names.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — February 27, 2026

Across 39 SEC 8-K filings on February 27, 2026, focused on US executive and director changes, the dominant theme is neutral leadership transitions with 18 resignations/retirements (all citing no disagreements with operations/policies), 10 appointments of experienced directors/executives, and 11 compensatory arrangements signaling retention efforts amid stable governance. Positive outliers include strategic hires like Northpointe Bancshares' ex-Comptroller Rodney Hood and Childrens Place's retail veteran Kim Roy, alongside compensation expansions such as Ambarella's 28% larger FY2027 bonus pool and Lesaka Technologies' salary hikes (e.g., CEO base to $503K). No explicit period-over-period financial trends (YoY/QoQ revenue/margins) are broadly disclosed, but comp increases proxy management confidence in 2026 performance targets like revenue and EBITDA goals. Portfolio-level patterns show banking sector churn (7/39 filings: retirements/appointments at Popular, BancFirst, Ohio Valley, Western New England, Northpointe) suggesting routine board refresh, while healthcare (5 filings) and tech (8 filings) exhibit similar neutral stability. Market implications favor monitoring Q1 2026 10-Qs for comp exhibit details and AGMs for board impacts, with low overall materiality (avg 5/10) implying minimal near-term volatility but opportunities in underfollowed hires.

39 high priority 39 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — February 27, 2026

Across 64 8-K filings in the USA Corporate Distress & Bankruptcy intelligence stream on Feb 27, 2026, dominant themes include proactive debt refinancings and equity offerings amid liquidity pressures, with 25+ companies announcing new notes, amendments, or credit facilities (e.g., Wyndham $650M at 5.625%, WESCO $1.5B at 5.25-5.50%) to repay higher-cost debt, signaling managed distress rather than acute insolvency. However, 8 companies face critical Nasdaq compliance failures, including delisting notices (Datavault AI, reAlpha Tech, Envoy Medical) and bid price deficiencies below $1.00 for 30+ days (Jupiter Neurosciences, Ensysce, Tenon Medical), heightening bankruptcy risks for micro-caps. No explicit YoY/QoQ revenue declines noted, but distressed financing terms proliferate: 28.6% discount on IMAC $175k note, 15% OID on Kinetic Seas $148.5k note, vs. investment-grade refis like Royal Caribbean $2.5B at 4.75-5.25%. Capital allocation tilts to debt repayment (e.g., Fold Holdings extinguished $66.3M notes) and working capital, with positive outliers like Sphere 3D regaining compliance. Portfolio-level: small-cap biotech/tech (15/64) shows 60% negative/mixed sentiment on compliance woes; broader market access to capital mitigates systemic distress. Actionable implication: short delisting risks, long refi beneficiaries with lower rates improving D/E ratios.

64 high priority 64 total filings
· daily

US SEC Trading Suspension Halt Orders — February 27, 2026

Across 8 8-K filings in the USA Trading Suspensions stream, a pervasive theme of Nasdaq Capital Market compliance failures dominates, with 7/8 companies facing negative developments including minimum bid price deficiencies below $1.00 for 30 consecutive business days (Jupiter Neurosciences, Ensysce Biosciences, Tenon Medical), MVLS shortfalls below $35M (Jupiter), late 10-Q filings (CIMG), and outright delisting notices (Datavault AI, reAlpha Tech, Envoy Medical), signaling acute liquidity and visibility risks. Sphere 3D stands out positively, regaining bid price compliance after a year-long issue resolved as of Feb 26, 2026. No period-over-period financial trends, insider trading activity, capital allocation details, guidance changes, or operational metrics were disclosed in any filing, focusing intelligence purely on regulatory halts and delisting trajectories. Portfolio-level implications include heightened delisting cascade risks for microcap biotech, AI/tech, and medtech names, with 180-day compliance windows clustering around Aug 24-25, 2026, potentially triggering trading suspensions or OTC transfers that erode 50-90% of value historically. Common pattern: trading remains uninterrupted short-term, but failure rates exceed 60% for bid price cures without reverse splits. Investors face immediate action needs to trim exposure amid zero offsetting positives like insider buys or dividend hikes.

8 high priority 8 total filings
· daily

US Corporate Board Director Changes SEC Filings — February 27, 2026

Across 36 SEC 8-K filings dated February 27, 2026, focused on USA Board Room Changes, the dominant theme is elevated executive and board churn with 18 resignations/retirements (mostly planned, no disagreements cited) and 12 appointments/promotions, signaling routine refreshment amid neutral sentiment in 85% of cases. Positive signals emerge from compensation expansions (e.g., Ambarella's FY2027 bonus pool 28% larger YoY, Lesaka's CEO salary to $503K) and high-profile hires (e.g., Northpointe's ex-regulator Rodney Hood, Aurora's ex-Meta CFO David Wehner), indicating retention efforts in growth sectors like fintech and tech. No broad period-over-period financial deteriorations noted, but unknown details in 11 Item 5.02 filings (e.g., Trimas, Smurfit Westrock) raise opacity risks; forward-looking comp plans target 2026 performance with upside to 200% bonuses. Financials/banks show highest volume (9 filings), suggesting sector-wide governance tuning ahead of AGMs. Portfolio implications: leadership stability generally intact, but monitor small caps (materiality 7-9/10) for execution risks; actionable alpha in comp hikes signaling management conviction.

36 high priority 36 total filings
· daily

US Merger & Acquisition SEC Filings — February 27, 2026

A surge in SPAC activity dominates the 9 filings from February 27, 2026, with 3 new SPAC IPOs raising a combined $586M ($125M Clearthink, $261M MOZAYYX upsized, $200M TRG Latin America), signaling robust investor appetite for blank-check companies targeting financial services, general M&A, and Latin America. De-SPAC progress is evident in Real Asset Acquisition Corp.'s definitive agreement with IQM Finland for quantum computing (potential Nasdaq listing) and Voyager Acquisition Corp.'s merger approval with VERAXA Biotech (Nasdaq: VRXA post-close). Avidity Biosciences reports a completed takeover with change of control, delisting, and agreement termination, marking a rare public-to-private shift. Vague filings from Abony, Roman DBDR, and Miluna highlight undisclosed M&A or governance events amid neutral sentiment. No period-over-period financial trends available across filings, but transaction volumes indicate heightened M&A momentum in tech/biotech/SPACs versus subdued traditional M&A. Capital allocation absent; forward-looking catalysts include IPO closings Feb 25-27, 2026, and conference calls. Implications: SPAC IPO boom offers entry points for merger arbitrage, while delisting/takeover in Avidity flags liquidity risks.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — February 27, 2026

Across 94 overnight SEC 8-K filings from Feb 26-27, 2026, the dominant theme is a surge in earnings-related disclosures (approx. 40 filings with Item 2.02), signaling peak earnings season with neutral sentiment in all cases due to undisclosed quantitative metrics like YoY/QoQ revenue growth or margins. A notable cluster of 15+ material definitive agreements (Item 1.01) points to heightened M&A activity across sectors like pharma, energy, and tech, potentially indicating consolidation plays though terms remain undisclosed. No insider trading activity, capital allocation details (dividends/buybacks), or forward-looking guidance changes are disclosed in any filing, limiting precise trend synthesis; however, period-over-period comparisons are absent across the board. One critical bearish outlier: Datavault AI Inc. delisting notice (materiality 10/10). Portfolio-level patterns show pharma/biotech (12+ filings) and energy/funds (15+) leading volume, with overall low-medium risk and neutral-to-mixed sentiment implying stable but opaque pre-market positioning. Actionable implication: Monitor exhibits/press releases for hidden beats/misses in high-materiality earnings (avg materiality 6-8/10); M&A clusters offer alpha if accretive.

21 high priority 73 medium 94 total filings
· daily

Biotech Small-Cap Approvals — February 26, 2026

A cluster of 5 approvals for BRIVARACETAM (1 bullish, 4 neutral ANDAs) signals intensifying generic competition, likely eroding pricing for originators while enabling portfolio expansion for small-cap generics firms. Vanda Pharms' NME approval for milsaperidone stands out as a high-potential novel asset with exclusivity. Neutral overall due to unspecified indications across 7/8 records, limiting market sizing; no risks beyond routine generic pressures.

8 total filings
· daily

New Drug Approvals (Original) — February 26, 2026

A cluster of five Brivaracetam approvals (one bullish original for Hainan Poly, four neutral ANDAs) signals imminent generic erosion in the US market, pressuring originator revenues while enabling volume-driven growth for generic sponsors. Bullish catalysts include Vanda Pharms' NME approval for milsaperidone and Hainan Poly's Brivaracetam nod, marking rare novel entries amid seven standard-review approvals. Neutral impacts dominate from unspecified indications across all records, limiting precise market sizing but highlighting generic portfolio expansions for Asian and specialty firms.

8 total filings
· daily

Federal Professional Services Contracts — February 26, 2026

Ameresco Inc. won a $217M firm fixed-price GSA delivery order for 19-year deep energy retrofits at 25 federal buildings in Region 5, signaling strong federal commitment to energy savings programs. This provides long-term revenue stability with $11.8M in options, but execution risks loom due to the extended timeline and no initial outlays. Investors should view this as a bullish catalyst for energy services firms targeting government contracts.

1 total filings